NewAmsterdam Pharma (NAMS) Projected to Post Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

NewAmsterdam Pharma Stock Up 1.8%

NASDAQ:NAMS opened at $35.24 on Wednesday. The stock has a market cap of $4.00 billion, a P/E ratio of -17.19 and a beta of 0.06. The business’s 50-day moving average price is $34.03 and its two-hundred day moving average price is $32.41. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $42.00.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 32,612 shares of the stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $774,425.40. This represents a 57.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the sale, the insider directly owned 73,481 shares in the company, valued at approximately $2,443,243.25. The trade was a 7.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 298,647 shares of company stock valued at $10,236,050. Corporate insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently added to or reduced their stakes in NAMS. Wells Fargo & Company MN boosted its holdings in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Geode Capital Management LLC boosted its stake in NewAmsterdam Pharma by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after acquiring an additional 437 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in NewAmsterdam Pharma by 4.5% in the second quarter. BNP Paribas Financial Markets now owns 29,277 shares of the company’s stock worth $530,000 after purchasing an additional 1,257 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of NewAmsterdam Pharma by 3.4% during the third quarter. Legal & General Group Plc now owns 45,738 shares of the company’s stock valued at $1,301,000 after purchasing an additional 1,503 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NAMS. Royal Bank Of Canada upped their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Needham & Company LLC increased their price target on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. The Goldman Sachs Group lifted their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Leerink Partners reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.